HA 29

an inhibitor of thromboxane A2 and prostaglandin endoperoxide receptors

Also Known As:

2-((3-methoxyphenyl)methyl)pyrano(2-3-c)pyrazol-6(1H)-one; HA-29; Pyrano(2,3-c)pyrazol-6(2H)-one, 2-((3-methoxyphenyl)methyl)-3,4-dimethyl-

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Hyperandrogenism 08/01/2011 - "There were four phenotypes of PCOS: 56/127 (44.09%) of the patients were polycystic ovaries on ultrasound (PCO) + oligo or anovulation (O) + biochemical and/or clinical hyperandrogenism (HA), 29/127 (22.84%) were HA+O, 24/127 (18.90%) were PCO+O and 18/127 (14.17%) were HA+PCO. "
2.	Anovulation 08/01/2011 - "There were four phenotypes of PCOS: 56/127 (44.09%) of the patients were polycystic ovaries on ultrasound (PCO) + oligo or anovulation (O) + biochemical and/or clinical hyperandrogenism (HA), 29/127 (22.84%) were HA+O, 24/127 (18.90%) were PCO+O and 18/127 (14.17%) were HA+PCO. "